Linezolid induced pancytopenia in a patient of extensively drug-resistant pulmonary tuberculosis: An unusual outcome
Linezolid (Lnz) is the first oxazolidinones to be developed and introduced in clinical use. Its use is growing by day and day in the treatment of resistant pulmonary tuberculosis (TB). Lnz has been associated with adverse hematological effects, primarily thrombocytopenia. But pancytopenia is a very...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer Medknow Publications
2016-01-01
|
| Edice: | The Journal of Association of Chest Physicians |
| Témata: | |
| On-line přístup: | http://www.jacpjournal.org/article.asp?issn=2320-8775;year=2016;volume=4;issue=1;spage=21;epage=23;aulast=Garg |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|